中国临床药理学杂志2018，Vol.34Issue(2)：188-192,5.DOI:10.13699/j.cnki.1001-6821.2018.02.026
选择性5-羟色胺再摄取抑制药的药物基因组学研究现状
Advances in pharmacogenomics of selective serotonin reuptake inhibitors
摘要
Abstract
At present,depression is mainly treated by drugs,while the remission rate of the first-line antidepressant selective serotonin reuptake inhibitor is only about 60％-70％.Many studies showed that the gene polymorphisms might be important factors influencing inter individual differences in drug reactions.Recent pharmacogenomics researches suggested that some related genes may affect the efficacy of selective serotonin reuptake inhibitor in the world.Here we briefly reviewed the pharmacogenomic research progress of several commonly used selective serotonin reuptake inhibitors,such as fluoxetine and sertraline from the aspect of clinical efficacy.关键词
选择性5-HT再摄取抑制药/疗效/药物基因组学Key words
selective serotonin reuptake inhibitor/efficacy/pharmacogenomics分类
医药卫生引用本文复制引用
周珊,黄民,王雪丁..选择性5-羟色胺再摄取抑制药的药物基因组学研究现状[J].中国临床药理学杂志,2018,34(2):188-192,5.
